Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 7.

Oberholzer, P A; Kee, D; Dziunycz, P; Sucker, A; Kamsukom, N; Jones, R; Roden, C; Chalk, C J; Ardlie, K; Palescandolo, E; Piris, A; Macconaill, L E; Robert, C; Hofbauer, G F L; McArthur, G A; Schadendorf, D; Garraway, L A (2012). RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors. Journal of Clinical Oncology, 30(3):316-321.

Lin, W M; Lewis, J M; Filler, R B; Modi, B G; Carlson, K R; Reddy, S; Thornberg, A; Saksena, G; Umlauf, S; Oberholzer, P A; Karpova, M; Getz, G; Mane, S; Garraway, L A; Dummer, R; Berger, C L; Edelson, R L; Girardi, M (2012). Characterization of the DNA copy-number genome in the blood of cutaneous T-cell lymphoma patients. Journal of Investigative Dermatology, 132:188-197.

Kiessling, M K; Oberholzer, P A; Mondal, C; Karpova, M B; Zipser, M C; Lin, W M; Girardi, M; MacConaill, L E; Kehoe, S M; Hatton, C; French, L E; Garraway, L A; Polier, G; Süss, D; Klemke, C D; Krammer, P H; Gülow, K; Dummer, R (2011). High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade. Blood, 117(8):2433-2440.

Johannessen, C M; Boehm, J S; Kim, S Y; Thomas, S R; Wardwell, L; Johnson, L A; Emery, C M; Stransky, N; Cogdill, A P; Barretina, J; Caponigro, G; Hieronymus, H; Murray, R R; Salehi-Ashtiani, K; Hill, D E; Vidal, M; Zhao, J J; Yang, X; Alkan, O; Kim, S; Harris, J L; Wilson, C J; Myer, V E; Finan, P M; Root, D E; Roberts, T M; Golub, T; Flaherty, K T; Dummer, R; Weber, B L; Sellers, W R; Schlegel, R; Wargo, J A; Hahn, W C; Garraway, L A (2010). COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature, 468(7326):968-972.

Berger, M F; Levin, J Z; Vijayendran, K; Sivachenko, A; Adiconis, X; Maguire, J; Johnson, L A; Robinson, J; Verhaak, R G; Sougnez, C; Onofrio, R C; Ziaugra, L; Cibulskis, K; Laine, E; Barretina, J; Winckler, W; Fisher, D E; Getz, G; Meyerson, M; Jaffe, D B; Gabriel, S B; Lander, E S; Dummer, R; Gnirke, A; Nusbaum, C; Garraway, L A (2010). Integrative analysis of the melanoma transcriptome. Genome Research, 20(4):413-427.

Emery, C M; Vijayendran, K G; Zipser, M C; Sawyer, A M; Niu, L; Kim, J J; Hatton, C; Chopra, R; Oberholzer, P A; Karpova, M B; MacConaill, L E; Zhang, J; Gray, N S; Sellers, W R; Dummer, R; Garraway, L A (2009). MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proceedings of the National Academy of Sciences of the United States of America (PNAS), 106(48):20411-20416.

Lin, W M; Baker, A C; Beroukhim, R; Winckler, W; Feng, W; Marmion, J M; Laine, E; Greulich, H; Tseng, H; Gates, C; Hodi, F S; Dranoff, G; Sellers, W R; Thomas, R K; Meyerson, M; Golub, T R; Dummer, R; Herlyn, M; Getz, G; Garraway, L A (2008). Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Research, 68(3):664-673.

This list was generated on Sat Sep 23 02:55:36 2017 CEST.